Getting a Second Opinion on Your — Targeted Therapy Plan

A pathology and molecular review typically takes one to two weeks from when the slides and reports reach the reviewing centre, assuming your tissue sample is adequate. You almost always use stored tissue from your original biopsy rather than having a new procedure. A brief review period before starting a targeted drug is generally considered worthwhile, because starting the right drug a fortnight later is preferable to starting the wrong one immediately. If your oncologist has said your situation is urgent and cannot wait, discuss the timeline directly — in genuinely urgent cases, treatment can begin while the review is in progress.

A disagreement between two opinions is information, not a crisis. It usually means that the available evidence supports more than one reasonable approach, or that one centre has identified a test result the other did not have. When two experienced oncologists give different recommendations, the right response is to ask each of them to explain their reasoning explicitly — in writing if possible. You can then decide which recommendation you understand and trust more, or seek a third opinion from a molecular tumour board. Disagreement between centres is more common in rare cancers and in cases where molecular testing was incomplete.

This is one of the most important reasons to seek a second opinion. If you have not seen a report listing specific mutations, gene fusions, or other molecular findings in your tumour tissue — not just a PD-L1 score, but a broader panel — ask your oncologist whether next-generation sequencing has been done. NCCN guidance recommends comprehensive molecular profiling for most advanced solid tumours before a targeted treatment decision is made. A specialist centre performing a second opinion will often order additional testing as part of their review, usually on the same stored biopsy tissue.

Yes. CION's oncology teams review pathology, molecular testing reports, and treatment plans across more than 35 centres in Telangana and Andhra Pradesh. Complex cases are reviewed at tumour board meetings where multiple specialists consider the case together. Response-assessment scans such as PET-CT are coordinated with partner imaging centres. CION does not provide CAR-T or cell therapy; if that is being considered for you, you would be referred to a centre that offers it. To arrange a review, contact the nearest CION centre with your available reports.

You are entitled to copies of your records and to borrow your biopsy slides. Ask the pathology department directly for the slides — they are lent rather than given permanently, and the reviewing centre will return them. For reports, the medical records office is usually the right starting point. Bring an ID, your hospital registration number, and a written request. Some hospitals charge a small administrative fee. Allow a few days for the request to be processed. If you are asking for digital scans of slides rather than physical glass, availability varies by centre — ask specifically when you make the request.

Confidence in the diagnosis and treatment plan is good, but a second opinion is not a check on confidence — it is a check on completeness. An oncologist can be entirely right about what they have tested and still not have ordered a test that a more specialised centre would consider routine. This is particularly true for rarer cancer types, for cancers now treated with a growing number of targeted options, and for any case where the molecular testing report you received was brief or limited to one or two markers. Seeking a second opinion when you feel uncertain is not an unusual thing to do. It is the standard advice from every major oncology guideline body.